Abstract:Abstract Recent next-generation sequencing experiments have brought success in identifying cancer genes that were highly frequently mutated in tumors. As genomic sequencing experiments continue to identify large numbers of novel cancer mutations, one big challenge will be distinguishing driver mutations from passenger mutations. Driver mutations are the ones that have a role in oncogenesis or in the cancer phenotype, whereas passenger mutations are co-traveler that accumulate through DNA replication but are irrelevant to tumor development. From statistical point of view, driver genes are defined as those for which the non-silent mutation rate is significantly greater than a background (or passenger) mutation rate estimated from silent mutations. Statistical methods are now actively being developed to attempt to assess functional significance of a mutated gene in cancer sequencing studies. However, embedding biological knowledge on mutational process in tumors into statistical models is not trivial. These biological considerations include length of protein coding regions, gene structure, transcript isoforms, difference in mutation types, variation in background mutation rates, redundancy of the genetic code, multiple mutations in one gene, and functional consequence of different tumor types. They have not yet been fully addressed by current methods and tools for identifying driver genes. Driver mutations could be either common or rare among tumors. Identification of rare driver mutations may pose a potential challenge. In addition, mutation in one member of a collection of functionally related genes may result in the same net effect, and/or mutations in certain genes may be observed less frequently if they play functional roles in later stages of tumor development. At the pathway level, the frequency of rare driver mutations is accumulated in that pathway which warrants sufficient detection power. Thus, there is an increasing interest in the identification of driver pathways in tumor formation and progression. To meet these challenges, we developed a tool-DrGaP for identify driver genes and pathways in cancer sequencing studies. We introduced the Poisson processes to model the random nature of somatic mutation under no selection pressure. The new model can handle the identification of both driver genes and pathways or any gene sets in the same statistical framework. The new tool provides several significant improvements and increased power over current existing methods through simulations. To illustrate its utility, we applied the DrGaP to analysis of a recent lung cancer sequencing study. The DrGaP identified a few novel driver genes that were missed by previous methods, demonstrating its high accuracy and sensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3971. doi:1538-7445.AM2012-3971

PTMsnp: A Web Server for the Identification of Driver Mutations That Affect Protein Post-translational Modification

PTM-ssMP: A Web Server for Predicting Different Types of Post-translational Modification Sites Using Novel Site-specific Modification Profile

AWESOME: a Database of SNPs That Affect Protein Post-Translational Modifications.

Mtctscan: a Comprehensive Platform for Annotation and Prioritization of Mutations Affecting Drug Sensitivity in Cancers

Abstract 3971: DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies

Tsnad: an Integrated Software for Cancer Somatic Mutation and Tumour-Specific Neoantigen Detection

DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies.

PTMD 2.0: an updated database of disease-associated post-translational modifications

PTMD: A Database of Human Disease-associated Post-translational Modifications

CanPredict: a Computational Tool for Predicting Cancer-Associated Missense Mutations

Identification of Driver Network Modules in Protein-Protein Interaction Network Using Patient Mutation Profiles

Recent Progress in Predicting Posttranslational Modification Sites in Proteins

Analysis of Mutations in Precision Oncology using The Automated, Accurate, and User-Friendly Web Tool PredictONCO

Recent Progress in Predicting Posttranslational Modification Sites in Proteins.

dbPTM 2025 update: comprehensive integration of PTMs and proteomic data for advanced insights into cancer research

PhosSNP for Systematic Analysis of Genetic Polymorphisms That Influence Protein Phosphorylation*

SysPIMP: the Web-Based Systematical Platform for Identifying Human Disease-Related Mutated Sequences from Mass Spectrometry

An Integrated Framework for Identifying Mutated Driver Pathway and Cancer Progression.

MPTM: A tool for mining protein post-translational modifications from literature.

Systematic Characterization of Somatic Mutation-Mediated Microrna Regulatory Network Perturbations

Distinguishing Driver Missense Mutations from Benign Polymorphisms in Breast Cancer.